Literature DB >> 17007029

Inhibition of hepatitis B virus production by Boehmeria nivea root extract in HepG2 2.2.15 cells.

Kai-Ling Huang1, Yiu-Kay Lai, Chih-Chien Lin, Jia-Ming Chang.   

Abstract

AIM: To explore the anti-hepatitis B virus (HBV) effects of Boehmeria nivea (B. nivea) root extract (BNE) by using the HepG2 2.2.15 cell model system.
METHODS: Hepatitis B surface antigen (HBsAg), hepatitis B virus e antigen (HBeAg), and HBV DNA were measured by using ELISA and real-time PCR, respectively. Viral DNA replication and RNA expression were determined by using Southern and Northern blot, respectively.
RESULTS: In HepG2 2.2.15 cells, HBeAg (60%, P < 0.01) and particle-associated HBV DNA (> 99%, P < 0.01) secretion into supernatant were significantly inhibited by BNE at a dose of 100 mg/L, whereas the HBsAg was not inhibited. With different doses of BNE, the reduced HBeAg was correlated with the inhibition of HBV DNA. The anti-HBV effect of BNE was not caused by its cytotoxicity to cells or inhibition of viral DNA replication and RNA expression.
CONCLUSION: BNE could effectively reduce the HBV production and its anti-HBV machinery might differ from the nucleoside analogues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17007029      PMCID: PMC4088177          DOI: 10.3748/wjg.v12.i35.5721

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Limited proteolysis induces woodchuck hepatitis virus infectivity for human HepG2 cells.

Authors:  X Lu; T Hazboun; T Block
Journal:  Virus Res       Date:  2001-01       Impact factor: 3.303

2.  Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review.

Authors:  J Liu; H Lin; H McIntosh
Journal:  J Viral Hepat       Date:  2001-09       Impact factor: 3.728

Review 3.  Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?

Authors:  E H C J Buster; H L A Janssen
Journal:  Neth J Med       Date:  2006-06       Impact factor: 1.422

Review 4.  Lamivudine resistance in hepatitis B: mechanisms and clinical implications.

Authors:  K P Fischer; K S Gutfreund; D L Tyrrell
Journal:  Drug Resist Updat       Date:  2001-04       Impact factor: 18.500

5.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

Authors:  Ching-Lung Lai; Mohamed Rosmawati; Judy Lao; Hans Van Vlierberghe; Frank H Anderson; Neal Thomas; Deborah Dehertogh
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

6.  A small molecule inhibits and misdirects assembly of hepatitis B virus capsids.

Authors:  Adam Zlotnick; Pablo Ceres; Sushmita Singh; Jennifer M Johnson
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids.

Authors:  Karl Deres; Claus H Schröder; Arnold Paessens; Siegfried Goldmann; Hans Jörg Hacker; Olaf Weber; Thomas Krämer; Ulrich Niewöhner; Ulrich Pleiss; Jürgen Stoltefuss; Erwin Graef; Diana Koletzki; Ralf N A Masantschek; Anja Reimann; Rainer Jaeger; Rainer Gross; Bernhard Beckermann; Karl-Heinz Schlemmer; Dieter Haebich; Helga Rübsamen-Waigmann
Journal:  Science       Date:  2003-02-07       Impact factor: 47.728

8.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

Authors:  Peter Angus; Rhys Vaughan; Shelly Xiong; Huiling Yang; William Delaney; Craig Gibbs; Carol Brosgart; Danielle Colledge; Rosalind Edwards; Anna Ayres; Angeline Bartholomeusz; Stephen Locarnini
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

9.  Use of complementary and alternative medicine in patients with liver disease.

Authors:  Doris B Strader; Bruce R Bacon; Karen L Lindsay; Douglas R La Brecque; Timothy Morgan; Elizabeth C Wright; Jeff Allen; M Farooq Khokar; Jay H Hoofnagle; Leonard B Seeff
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

10.  Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model.

Authors:  O Weber; K-H Schlemmer; E Hartmann; Ina Hagelschuer; A Paessens; E Graef; K Deres; S Goldmann; U Niewoehner; J Stoltefuss; D Haebich; H Ruebsamen-Waigmann; Stefan Wohlfeil
Journal:  Antiviral Res       Date:  2002-05       Impact factor: 5.970

View more
  15 in total

1.  Anti-hepatitis B virus activity of Boehmeria nivea leaf extracts in human HepG2.2.15 cells.

Authors:  Jingchen Wei; Lianku Lin; Xiaojian Su; Shaoyan Qin; Qing Xu; Zunian Tang; Yan Deng; Yuehan Zhou; Songqing He
Journal:  Biomed Rep       Date:  2013-11-22

2.  In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy.

Authors:  L-L Fu; J Liu; Y Chen; F-T Wang; X Wen; H-Q Liu; M-Y Wang; L Ouyang; J Huang; J-K Bao; Y-Q Wei
Journal:  Cell Prolif       Date:  2014-06-26       Impact factor: 6.831

3.  Antiviral Activity of Cananga odorata Against Hepatitis B Virus.

Authors:  Puguh Indrasetiawan; Chie Aoki-Utsubo; Muhammad Hanafi; Sri Hartati; Tutik Sri Wahyuni; Masanori Kameoka; Yoshihiko Yano; Hak Hotta; Yoshitake Hayashi
Journal:  Kobe J Med Sci       Date:  2019-11-12

Review 4.  Multi-Omics Approach in the Identification of Potential Therapeutic Biomolecule for COVID-19.

Authors:  Rachana Singh; Pradhyumna Kumar Singh; Rajnish Kumar; Md Tanvir Kabir; Mohammad Amjad Kamal; Abdur Rauf; Ghadeer M Albadrani; Amany A Sayed; Shaker A Mousa; Mohamed M Abdel-Daim; Md Sahab Uddin
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

5.  Identification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®.

Authors:  Iao-Fai Lam; Min Huang; Margaret Dah-Tysr Chang; Pei-Wun Yao; Yu-Ting Chou; Sim-Kun Ng; Ying-Lin Tsai; Yu-Chang Lin; Yun-Feng Zhang; Xiao-Yuan Yang; Yiu-Kay Lai
Journal:  Chin Med       Date:  2017-04-24       Impact factor: 5.455

6.  Potentials of plant-based substance to inhabit and probable cure for the COVID-19.

Authors:  Israt Jahan; Ahmet Onay
Journal:  Turk J Biol       Date:  2020-06-21

7.  Genomics approaches to synthesis plant-based biomolecules for therapeutic applications to combat SARS-CoV-2.

Authors:  Namisha Sharma; Mehanathan Muthamilarasan; Ashish Prasad; Manoj Prasad
Journal:  Genomics       Date:  2020-07-24       Impact factor: 5.736

8.  The Anti-hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-viremia SCID Mice.

Authors:  Jia-Ming Chang; Kai-Ling Huang; Thomas Ta-Tung Yuan; Yiu-Kay Lai; Le-Mei Hung
Journal:  Evid Based Complement Alternat Med       Date:  2008-01-07       Impact factor: 2.629

Review 9.  A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-Cov.

Authors:  Rambod Abiri; Hazandy Abdul-Hamid; Oksana Sytar; Ramin Abiri; Eduardo Bezerra de Almeida; Surender K Sharma; Victor P Bulgakov; Randolph R J Arroo; Sonia Malik
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

10.  Enhanced recombinant protein production and differential expression of molecular chaperones in sf-caspase-1-repressed stable cells after baculovirus infection.

Authors:  Yiu-Kay Lai; John T-A Hsu; Chih-Chieh Chu; Teng-Yuan Chang; Kao-Lu Pan; Chih-Chien Lin
Journal:  BMC Biotechnol       Date:  2012-11-07       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.